Biological markers in osteoarthritis

Bone

Volumn 51, Issue 2, 2012, Pages 265-277

  Rousseau, J Ch ^a   Garnero, P ^a,b  

^a UNIVERSITÉ DE LYON   (France)

^b Cisbio Bioassays ^*  (France)

Author keywords

Biomarkers; BIPED classification; Osteoarthritis

Indexed keywords

AGGRECAN; AGGRECANASE 1; AGGRECANASE 2; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CHONDROITIN SULFATE; COLLAGEN TYPE 2; COLLAGENASE 3; ENDOGLIN; ESTROGEN; GLUCOSAMINE; HYALURONIC ACID; INTERLEUKIN 1BETA; LEPTIN; MYELOPEROXIDASE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOGENIC PROTEIN 1; OSTEOPONTIN; PADGEM PROTEIN; PLACEBO; REACTIVE OXYGEN METABOLITE; SIALOPROTEIN; STROMELYSIN; STRONTIUM RANELATE; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNINDEXED DRUG;

ARTICLE; ARTICULAR CARTILAGE; BONE METABOLISM; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE MARKER; DRUG ACTIVITY; HAND OSTEOARTHRITIS; HAPLOTYPE; HIP OSTEOARTHRITIS; HUMAN; INFLAMMATION; KNEE OSTEOARTHRITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PAGET BONE DISEASE; PATHOGENESIS; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN PROCESSING; SYNOVITIS; SYNOVIUM; TISSUE METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; OSTEOARTHRITIS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84861975988     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.04.001     Document Type: Article

References (160)

1. Oliviero F., Ramonda R., Punzi L. New horizons in osteoarthritis. Swiss Med Wkly 2010, 140:w13098.
2. Kraus VB, Nevitt M, Sandell LJ Summary of the OA biomarkers workshop 2009--biochemical biomarkers: biology, validation, and clinical studies. Osteoarthritis Cartilage 18:742-745.
3. Saxne T., Lindell M., Mansson B., Petersson I.F., Heinegard D. Inflammation is a feature of the disease process in early knee joint osteoarthritis. Rheumatology (Oxford) 2003, 42:903-904.
4. Sowers M., Jannausch M., Stein E., Jamadar D., Hochberg M., Lachance L. C-reactive protein as a biomarker of emergent osteoarthritis. Osteoarthritis Cartilage 2002, 10:595-601.
5. Bauer D.C., Hunter D.J., Abramson S.B., Attur M., Corr M., Felson D., et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 2006, 14:723-727.
6. Kraus V.B., Burnett B., Coindreau J., Cottrell S., Eyre D., Gendreau M., et al. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage 2011, 19:515-542.
7. Stewart A., Black A., Robins S.P., Reid D.M. Bone density and bone turnover in patients with osteoarthritis and osteoporosis. J Rheumatol 1999, 26:622-626.
8. Bettica P., Cline G., Hart D.J., Meyer J., Spector T.D. Evidence for increased bone resorption in patients with progressive knee osteoarthritis: longitudinal results from the Chingford study. Arthritis Rheum 2002, 46:3178-3184.
9. Sowers M., Lachance L., Jamadar D., Hochberg M.C., Hollis B., Crutchfield M., et al. The associations of bone mineral density and bone turnover markers with osteoarthritis of the hand and knee in pre- and perimenopausal women. Arthritis Rheum 1999, 42:483-489.
10. Debri E., RF, Heinegard D., Mengarellilholm S., Norgard M., Swensson O. Bone sialoprotein and osteopontin distribution at the osteocartilaginous interface. Clin Orthop 1996, 330:251.
11. Henrotin Y., Addison S., Kraus V., Deberg M. Type II collagen markers in osteoarthritis: what do they indicate?. Curr Opin Rheumatol 2007, 19:444-450.
12. Huebner J.L., Williams J.M., Deberg M., Henrotin Y., Kraus V.B. Collagen fibril disruption occurs early in primary guinea pig knee osteoarthritis. Osteoarthritis Cartilage 2009, 18:397-405.
13. Shinmei M., Ito K., Matsuyama S., Yoshihara Y., Matsuzawa K. Joint fluid carboxy-terminal type II procollagen peptide as a marker of cartilage collagen biosynthesis. Osteoarthritis Cartilage 1993, 1:121-128.
14. Nelson F., Dahlberg L., Laverty S., Reiner A., Pidoux I., Ionescu M., et al. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 1998, 102:2115-2125.
15. Rousseau J.C., Zhu Y., Miossec P., Vignon E., Sandell L.J., Garnero P., et al. Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2004, 12:440-447.
16. Garnero P., Ayral X., Rousseau J.C., Christgau S., Sandell L.J., Dougados M., et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002, 46:2613-2624.
17. Sharif M., Kirwan J., Charni N., Sandell L.J., Whittles C., Garnero P. A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis-association with disease progression. Rheumatology (Oxford) 2007, 46:938-943.
18. Bay-Jensen A.C., Tabassi N.C., Sondergaard L.V., Andersen T.L., Dagnaes-Hansen F., Garnero P., et al. The response to oestrogen deprivation of the cartilage collagen degradation marker, CTX-II, is unique compared with other markers of collagen turnover. Arthritis Res Ther 2009, 11:R9.
19. Oestergaard S., Sondergaard B.C., Hoegh-Andersen P., Henriksen K., Qvist P., Christiansen C., et al. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum 2006, 54:2441-2451.
20. Meulenbelt I., Kloppenburg M., Kroon H.M., Houwing-Duistermaat J.J., Garnero P., Hellio Le Graverand M.P., et al. Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study. Ann Rheum Dis 2006, 65:360-365.
21. Garnero P., Peterfy C., Zaim S., Schoenharting M. Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum 2005, 52:2822-2829.
22. Christgau S., Garnero P., Fledelius C., Moniz C., Ensig M., Gineyts E., et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001, 29:209-215.
23. Matyas J.R., Atley L., Ionescu M., Eyre D.R., Poole A.R. Analysis of cartilage biomarkers in the early phases of canine experimental osteoarthritis. Arthritis Rheum 2004, 50:543-552.
24. Mazzuca S.A., Brandt K.D., Eyre D.R., Katz B.P., Askew J., Lane K.A. Urinary levels of type II collagen C-telopeptide crosslink are unrelated to joint space narrowing in patients with knee osteoarthritis. Ann Rheum Dis 2006, 65:1055-1059.
25. Elsaid K.A., Chichester C.O. Review: collagen markers in early arthritic diseases. Clin Chim Acta 2006, 365:68-77.
26. Abramson S.B. Osteoarthritis and nitric oxide. Osteoarthritis Cartilage 2008, 16(Suppl. 2):S15-S20.
27. Deberg M., Labasse A., Christgau S., Cloos P., Bang Henriksen D., Chapelle J.P., et al. New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2005, 13:258-265.
28. Deberg M.A., Labasse A.H., Collette J., Seidel L., Reginster J.Y., Henrotin Y.E. One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis Cartilage 2005, 13:1059-1065.
29. Poole A.R., Ionescu M., Swan A., Dieppe P.A. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis. J Clin Invest 1994, 94:25-33.
30. Rizkalla G., Reiner A., Bogoch E., Poole A.R. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest 1992, 90:2268-2277.
31. Wakitani S., Okabe T., Kawaguchi A., Nawata M., Hashimoto Y. Highly sensitive ELISA for determining serum keratan sulphate levels in the diagnosis of OA. Rheumatology (Oxford) 2010, 49:57-62.
32. Clark A.G., Jordan J.M., Vilim V., Renner J.B., Dragomir A.D., Luta G., et al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum 1999, 42:2356-2364.
33. Catterall J.B., Hsueh M.F., Stabler T.V., McCudden C.R., Bolognesi M., Zura R., et al. Protein modification by deamidation indicates variations in joint extracellular matrix turnover. J Biol Chem 2012, 287:4640-4651.
34. Henrotin Y., Gharbi M., Mazzucchelli G., Dubuc J.E., De Pauw E., Deberg M. Fibulin-3 peptides (Fib3-1 and Fib3-2) are potential biomarkers of osteoarthritis. Arthritis Rheum 2012, [Jan 24, Electronic publication ahead of print].
35. Gineyts E., Garnero P., Delmas P.D. Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation. Rheumatology (Oxford) 2001, 40:315-323.
36. Elliott A.L., Kraus V.B., Luta G., Stabler T., Renner J.B., Woodard J., et al. Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project. Arthritis Rheum 2005, 52:105-111.
37. Johansen J.S., Hvolris J., Hansen M., Backer V., Lorenzen I., Price P.A. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 1996, 35:553-559.
38. Verzijl N., Bank R.A., TeKoppele J.M., DeGroot J. AGEing and osteoarthritis: a different perspective. Curr Opin Rheumatol 2003, 15:616-622.
39. Chen H.C., Shah S., Stabler T.V., Li Y.J., Kraus V.B. Biomarkers associated with clinical phenotypes of hand osteoarthritis in a large multigenerational family: the CARRIAGE family study. Osteoarthritis Cartilage 2008, 16:1054-1059.
40. Rousseau J.C., Chevrel G., Schott A.M., Garnero P. Increased cartilage type II collagen degradation in patients with osteogenesis imperfecta used as a human model of bone type I collagen alterations. Bone 2010, 46:897-900.
41. Bondeson J., Wainwright S.D., Lauder S., Amos N., Hughes C.E. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 2006, 8:R187.
42. Kaneko S., Satoh T., Chiba J., Ju C., Inoue K., Kagawa J. Interleukin-6 and interleukin-8 levels in serum and synovial fluid of patients with osteoarthritis. Cytokines Cell Mol Ther 2000, 6:71-79.
43. Steinbeck M.J., Nesti L.J., Sharkey P.F., Parvizi J. Myeloperoxidase and chlorinated peptides in osteoarthritis: potential biomarkers of the disease. J Orthop Res 2007, 25:1128-1135.
44. Deberg M., Dubuc J.E., Labasse A., Sanchez C., Quettier E., Bosseloir A., et al. One-year follow-up of Coll2-1, Coll2-1NO2 and myeloperoxydase serum levels in osteoarthritis patients after hip or knee replacement. Ann Rheum Dis 2008, 67:168-174.
45. Denoble A.E., Huffman K.M., Stabler T.V., Kelly S.J., Hershfield M.S., McDaniel G.E., et al. Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc Natl Acad Sci U S A 2011, 108:2088-2093.
46. Chevalier X., Conrozier T., Gehrmann M., Claudepierre P., Mathieu P., Unger S., et al. Tissue inhibitor of metalloprotease-1 (TIMP-1) serum level may predict progression of hip osteoarthritis. Osteoarthritis Cartilage 2001, 9:300-307.
47. Dean D.D., Martel-Pelletier J., Pelletier J.P., Howell D.S., Woessner J.F. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 1989, 84:678-685.
48. van Spil W.E., DeGroot J., Lems W.F., Oostveen J.C., Lafeber F.P. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthritis Cartilage 2010, 18:605-612.
49. Lohmander L.S., Yoshihara Y., Roos H., Kobayashi T., Yamada H., Shinmei M. Procollagen II C-propeptide in joint fluid: changes in concentration with age, time after knee injury, and osteoarthritis. J Rheumatol 1996, 23:1765-1769.
50. Lohmander L.S., Atley L.M., Pietka T.A., Eyre D.R. The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum 2003, 48:3130-3139.
51. Dragomir A.D., Kraus V.B., Renner J.B., Luta G., Clark A., Vilim V., et al. Serum cartilage oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology. Osteoarthritis Cartilage 2002, 10:687-691.
52. Kelman A., Lui L., Yao W., Krumme A., Nevitt M., Lane N.E. Association of higher levels of serum cartilage oligomeric matrix protein and N-telopeptide crosslinks with the development of radiographic hip osteoarthritis in elderly women. Arthritis Rheum 2006, 54:236-243.
53. Wakitani S., Nawata M., Kawaguchi A., Okabe T., Takaoka K., Tsuchiya T., et al. Serum keratan sulfate is a promising marker of early articular cartilage breakdown. Rheumatology (Oxford) 2007, 46:1652-1656.
54. Bleasel J.F., Poole A.R., Heinegard D., Saxne T., Holderbaum D., Ionescu M., et al. Changes in serum cartilage marker levels indicate altered cartilage metabolism in families with the osteoarthritis-related type II collagen gene COL2A1 mutation. Arthritis Rheum 1999, 42:39-45.
55. Cibere J., Zhang H., Garnero P., Poole A.R., Lobanok T., Saxne T., et al. Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthritis Rheum 2009, 60:1372-1380.
56. Hunter D.J. Advanced imaging in osteoarthritis. Bull NYU Hosp Jt Dis 2008, 66:251-260.
57. Peterfy C.G., Guermazi A., Zaim S., Tirman P.F., Miaux Y., White D., et al. Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage 2004, 12:177-190.
58. King K.B., Lindsey C.T., Dunn T.C., Ries M.D., Steinbach L.S., Majumdar S. A study of the relationship between molecular biomarkers of joint degeneration and the magnetic resonance-measured characteristics of cartilage in 16 symptomatic knees. Magn Reson Imaging 2004, 22:1117-1123.
59. Ding C., Garnero P., Cicuttini F., Scott F., Cooley H., Jones G. Knee cartilage defects: association with early radiographic osteoarthritis, decreased cartilage volume, increased joint surface area and type II collagen breakdown. Osteoarthritis Cartilage 2005, 13:198-205.
60. Garnero P., Piperno M., Gineyts E., Christgau S., Delmas P.D., Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001, 60:619-626.
61. Altman R.D. Early management of osteoarthritis. Am J Manag Care 2010, 16:S41-S47. Suppl. Management.
62. Kraus V.B., Nevitt M., Sandell L.J. Summary of the OA biomarkers workshop 2009-biochemical biomarkers: biology, validation, and clinical studies. Osteoarthritis Cartilage 2010, 18:742-745.
63. Rousseau J.C., Delmas P.D. Biological markers in osteoarthritis. Nat Clin Pract Rheumatol 2007, 3:346-356.
64. Rego-Perez I., Fernandez-Moreno M., Fernandez-Lopez C., Arenas J., Blanco F.J. Mitochondrial DNA haplogroups: role in the prevalence and severity of knee osteoarthritis. Arthritis Rheum 2008, 58:2387-2396.
65. Fernandez-Moreno M., Rego I., Carreira-Garcia V., Blanco F.J. Genetics in osteoarthritis. Curr Genomics 2008, 9:542-547.
66. Rego I., Fernandez-Moreno M., Fernandez-Lopez C., Gomez-Reino J.J., Gonzalez A., Arenas J., et al. Role of European mitochondrial DNA haplogroups in the prevalence of hip osteoarthritis in Galicia, Northern Spain. Ann Rheum Dis 2010, 69:210-213.
67. Valdes A.M., Styrkarsdottir U., Doherty M., Morris D.L., Mangino M., Tamm A., et al. Large scale replication study of the association between HLA class II/BTNL2 variants and osteoarthritis of the knee in European-descent populations. PLoS One 2011, 6:e23371.
68. Rego-Perez I., Fernandez-Moreno M., Deberg M., Pertega S., Fenandez-Lopez C., Oreiro N., et al. Mitochondrial DNA haplogroups modulate the serum levels of biomarkers in patients with osteoarthritis. Ann Rheum Dis 2010, 69:910-917.
69. Rego-Perez I., Fernandez-Moreno M., Deberg M., Pertega S., Fernandez-Lopez C., Oreiro N., et al. Mitochondrial DNA haplogroups and serum levels of proteolytic enzymes in patients with osteoarthritis. Ann Rheum Dis 2011, 70:646-652.
70. Chen H.C., Kraus V.B., Li Y.J., Nelson S., Haynes C., Johnson J., et al. Genome-wide linkage analysis of quantitative biomarker traits of osteoarthritis in a large, multigenerational extended family. Arthritis Rheum 2010, 62:781-790.
71. Blanco F.J., Rego I., Ruiz-Romero C. The role of mitochondria in osteoarthritis. Nat Rev Rheumatol 2011, 7:161-169.
72. Gao S.G., Li K.H., Zeng K.B., Tu M., Xu M., Lei G.H. Elevated osteopontin level of synovial fluid and articular cartilage is associated with disease severity in knee osteoarthritis patients. Osteoarthritis Cartilage 2010, 18:82-87.
73. Honsawek S., Tanavalee A., Yuktanandana P. Elevated circulating and synovial fluid endoglin are associated with primary knee osteoarthritis severity. Arch Med Res 2009, 40:590-594.
74. Pilichou A., Papassotiriou I., Michalakakou K., Fessatou S., Fandridis E., Papachristou G., et al. High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis. Clin Biochem 2008, 41:746-749.
75. Catterall J.B., Barr D., Bolognesi M., Zura R.D., Kraus V.B. Post-translational aging of proteins in osteoarthritic cartilage and synovial fluid as measured by isomerized aspartate. Arthritis Res Ther 2009, 11:R55.
76. Honsawek S., Chayanupatkul M., Tanavalee A., Sakdinakiattikoon M., Deepaisarnsakul B., Yuktanandana P., et al. Relationship of plasma and synovial fluid BMP-7 with disease severity in knee osteoarthritis patients: a pilot study. Int Orthop 2009, 33:1171-1175.
77. Ku J.H., Lee C.K., Joo B.S., An B.M., Choi S.H., Wang T.H., et al. Correlation of synovial fluid leptin concentrations with the severity of osteoarthritis. Clin Rheumatol 2009, 28:1431-1435.
78. Chayanupatkul M., Honsawek S. Soluble receptor for advanced glycation end products (sRAGE) in plasma and synovial fluid is inversely associated with disease severity of knee osteoarthritis. Clin Biochem 2010, 43:1133-1137.
79. Addison S., Coleman R.E., Feng S., McDaniel G., Kraus V.B. Whole-body bone scintigraphy provides a measure of the total-body burden of osteoarthritis for the purpose of systemic biomarker validation. Arthritis Rheum 2009, 60:3366-3373.
80. Kraus V.B., Kepler T.B., Stabler T., Renner J., Jordan J. First qualification study of serum biomarkers as indicators of total body burden of osteoarthritis. PLoS One 2010, 5:e9739.
81. Garnero P., Sornay-Rendu E., Arlot M., Christiansen C., Delmas P.D. Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study. Arthritis Rheum 2004, 50:3137-3144.
82. Garnero P., Mazieres B., Gueguen A., Abbal M., Berdah L., Lequesne M., et al. Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort. J Rheumatol 2005, 32:697-703.
83. Conrozier T., Poole A.R., Ferrand F., Mathieu P., Vincent F., Piperno M., et al. Serum concentrations of type II collagen biomarkers (C2C, C1, 2C and CPII) suggest different pathophysiologies in patients with hip osteoarthritis. Clin Exp Rheumatol 2008, 26:430-435.
84. Cheng T., Li F.F., Zhao S., Peng X.C., Zhang X.L. Soluble P selectin in synovial fluid level is correlated with the radiographic severity of knee osteoarthritis. Clin Chim Acta 2010, 411:1529-1531.
85. Meulenbelt I., Kloppenburg M., Kroon H.M., Houwing-Duistermaat J.J., Garnero P., Hellio-Le Graverand M.P., et al. Clusters of biochemical markers are associated with radiographic subtypes of osteoarthritis (OA) in subject with familial OA at multiple sites. The GARP study. Osteoarthritis Cartilage 2007, 15:379-385.
86. Davis C.R., Karl J., Granell R., Kirwan J.R., Fasham J., Johansen J., et al. Can biochemical markers serve as surrogates for imaging in knee osteoarthritis?. Arthritis Rheum 2007, 56:4038-4047.
87. Eckstein F., Le Graverand M.P., Charles H.C., Hunter D.J., Kraus V.B., Sunyer T., et al. Clinical, radiographic, molecular and MRI-based predictors of cartilage loss in knee osteoarthritis. Ann Rheum Dis 2011, 70:1223-1230.
88. Garnero P., Conrozier T., Christgau S., Mathieu P., Delmas P.D., Vignon E. Urinary type II collagen C-telopeptide levels are increased in patients with rapidly destructive hip osteoarthritis. Ann Rheum Dis 2003, 62:939-943.
89. Reijman M., Hazes J.M., Bierma-Zeinstra S.M., Koes B.W., Christgau S., Christiansen C., et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004, 50:2471-2478.
90. Mazieres B., Garnero P., Gueguen A., Abbal M., Berdah L., Lequesne M., et al. Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort. Ann Rheum Dis 2006, 65:354-359.
91. Dam E.B., Byrjalsen I., Karsdal M.A., Qvist P., Christiansen C. Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage 2009, 17:384-389.
92. Raynauld J.P., Martel-Pelletier J., Berthiaume M.J., Beaudoin G., Choquette D., Haraoui B., et al. Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Res Ther 2006, 8:R21.
93. Sugiyama S., Itokazu M., Suzuki Y., Shimizu K. Procollagen II C propeptide level in the synovial fluid as a predictor of radiographic progression in early knee osteoarthritis. Ann Rheum Dis 2003, 62:27-32.
94. Conrozier T., Saxne T., Fan C.S., Mathieu P., Tron A.M., Heinegard D., et al. Serum concentrations of cartilage oligomeric matrix protein and bone sialoprotein in hip osteoarthritis: a one year prospective study. Ann Rheum Dis 1998, 57:527-532.
95. Vilim V., Olejarova M., Machacek S., Gatterova J., Kraus V.B., Pavelka K. Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis Cartilage 2002, 10:707-713.
96. Hunter D.J., Li J., LaValley M., Bauer D.C., Nevitt M., DeGroot J., et al. Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study. Arthritis Res Ther 2007, 9:R108.
97. Berry P.A., Maciewicz R.A., Wluka A.E., Downey-Jones M.D., Forbes A., Hellawell C.J., et al. Relationship of serum markers of cartilage metabolism to imaging and clinical outcome measures of knee joint structure. Ann Rheum Dis 2010, 69:1816-1822.
98. Pavelka K., Forejtova S., Olejarova M., Gatterova J., Senolt L., Spacek P., et al. Hyaluronic acid levels may have predictive value for the progression of knee osteoarthritis. Osteoarthritis Cartilage 2004, 12:277-283.
99. Bruyere O., Collette J.H., Ethgen O., Rovati L.C., Giacovelli G., Henrotin Y.E., et al. Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis. J Rheumatol 2003, 30:1043-1050.
100. Sharif M., Kirwan J.R., Elson C.J., Granell R., Clarke S. Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years. Arthritis Rheum 2004, 50:2479-2488.
101. Bruyere O., Collette J., Kothari M., Zaim S., White D., Genant H., et al. Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study. Ann Rheum Dis 2006, 65:1050-1054.
102. Hellio Le Graverand M.P., Brandt K.D., Mazzuca S.A., Katz B.P., Buck R., Lane K.A., et al. Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis. Osteoarthritis Cartilage 2006, 14:1189-1195.
103. Chaganti R.K., Kelman A., Lui L., Yao W., Javaid M.K., Bauer D., et al. Change in serum measurements of cartilage oligomeric matrix protein and association with the development and worsening of radiographic hip osteoarthritis. Osteoarthritis Cartilage 2008, 16:566-571.
104. Sowers M.F., Karvonen-Gutierrez C.A., Yosef M., Jannausch M., Jiang Y., Garnero P., et al. Longitudinal changes of serum COMP and urinary CTX-II predict X-ray defined knee osteoarthritis severity and stiffness in women. Osteoarthritis Cartilage 2009, 17:1609-1614.
105. Dam E.B., Loog M., Christiansen C., Byrjalsen I., Folkesson J., Nielsen M., et al. Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers. Arthritis Res Ther 2009, 11:R115.
106. Cahue S., Sharma L., Dunlop D., Ionescu M., Song J., Lobanok T., et al. The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. Osteoarthritis Cartilage 2007, 15:819-823.
107. Cheung P.P., Gossec L., Dougados M. What are the best markers for disease progression in osteoarthritis (OA)?. Best Pract Res Clin Rheumatol 2010, 24:81-92.
108. Chapple C.M., Nicholson H., Baxter G.D., Abbott J.H. Patient characteristics that predict progression of knee osteoarthritis: a systematic review of prognostic studies. Arthritis Care Res (Hoboken) 2011, 63:1115-1125.
109. Belo J.N., Berger M.Y., Reijman M., Koes B.W., Bierma-Zeinstra S.M. Prognostic factors of progression of osteoarthritis of the knee: a systematic review of observational studies. Arthritis Rheum 2007, 57:13-26.
110. Pirotta M. Arthritis disease - the use of complementary therapies. Aust Fam Physician 2010, 39:638-640.
111. Zhang W., Nuki G., Moskowitz R.W., Abramson S., Altman R.D., Arden N.K., et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010, 18:476-499.
112. Reginster J.Y., Deroisy R., Rovati L.C., Lee R.L., Lejeune E., Bruyere O., et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-256.
113. Pavelka K., Gatterova J., Olejarova M., Machacek S., Giacovelli G., Rovati L.C. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002, 162:2113-2123.
114. Cibere J., Thorne A., Kopec J.A., Singer J., Canvin J., Robinson D.B., et al. Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers. J Rheumatol 2005, 32:896-902.
115. Mazieres B., Hucher M., Zaim M., Garnero P. Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2007, 66:639-645.
116. Naito K., Watari T., Furuhata A., Yomogida S., Sakamoto K., Kurosawa H., et al. Evaluation of the effect of glucosamine on an experimental rat osteoarthritis model. Life Sci 2010, 86:538-543.
117. Conrozier T., Balblanc J.C., Richette P., Mulleman D., Maillet B., Henrotin Y., et al. Early effect of hyaluronic acid intra-articular injections on serum and urine biomarkers in patients with knee osteoarthritis: an open-label observational prospective study. J Orthop Res 2012, 30:679-685.
118. Henrotin Y.C.T., Deberg M., Walliser-Lohse A., Richette P., Mulleman D., Maillet B., et al. Early decrease of serum biomarkers of type II collagen degradation (Coll2-1) and joint inflammation (Coll2-1 NO2) by hyaluronic acid intra-articular injections in patients with knee osteoarthritis. Ann Rheum Dis 2011, 70:395.
119. Renkiewicz R., Qiu L., Lesch C., Sun X., Devalaraja R., Cody T., et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum 2003, 48:1742-1749.
120. Leff R.L., Elias I., Ionescu M., Reiner A., Poole A.R. Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor. J Rheumatol 2003, 30:544-549.
121. Settle S., Vickery L., Nemirovskiy O., Vidmar T., Bendele A., Messing D., et al. Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis: confirmation by multivariate analysis that modulation of type II collagen and aggrecan degradation peptides parallels pathologic changes. Arthritis Rheum 2010, 62:3006-3015.
122. Chockalingam P.S., Sun W., Rivera-Bermudez M.A., Zeng W., Dufield D.R., Larsson S., et al. Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthritis Cartilage 2011, 19:315-323.
123. Kwan Tat S., Lajeunesse D., Pelletier J.P., Martel-Pelletier J. Targeting subchondral bone for treating osteoarthritis: what is the evidence?. Best Pract Res Clin Rheumatol 2010, 24:51-70.
124. Hayami T., Pickarski M., Zhuo Y., Wesolowski G.A., Rodan G.A., Duong le T. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone 2006, 38:234-243.
125. Bailey A.J., Sims T.J., Knott L. Phenotypic expression of osteoblast collagen in osteoarthritic bone: production of type I homotrimer. Int J Biochem Cell Biol 2002, 34:176-182.
126. Hayami T., Pickarski M., Wesolowski G.A., McLane J., Bone A., Destefano J., et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum 2004, 50:1193-1206.
127. Muehleman C., Green J., Williams J.M., Kuettner K.E., Thonar E.J., Sumner D.R. The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage. Osteoarthritis Cartilage 2002, 10:226-233.
128. Garnero P. New biochemical markers of osteoarthritis. Aging health 2006, 2:639-647.
129. Spector T.D., Conaghan P.G., Buckland-Wright J.C., Garnero P., Cline G.A., Beary J.F., et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005, 7:R625-R633.
130. Bingham C.O., Buckland-Wright J.C., Garnero P., Cohen S.B., Dougados M., Adami S., et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006, 54:3494-3507.
131. Garnero P., Aronstein W.S., Cohen S.B., Conaghan P.G., Cline G.A., Christiansen C., et al. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthritis Cartilage 2008, 16:660-666.
132. Alexandersen P., Karsdal M.A., Qvist P., Reginster J.Y., Christiansen C. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. Bone 2007, 40:218-222.
133. Bruyere O., Delferriere D., Roux C., Wark J.D., Spector T., Devogelaer J.P., et al. Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 2008, 67:335-339.
134. Sondergaard B.C., Oestergaard S., Christiansen C., Tanko L.B., Karsdal M.A. The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model. Arthritis Rheum 2007, 56:2674-2678.
135. Nielsen R.H., Bay-Jensen A.C., Byrjalsen I., Karsdal M.A. Oral salmon calcitonin reduces cartilage and bone pathology in an osteoarthritis rat model with increased subchondral bone turnover. Osteoarthritis Cartilage 2011, 19:466-473.
136. Karsdal M.A., Byrjalsen I., Henriksen K., Riis B.J., Lau E.M., Arnold M., et al. The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study. Osteoarthritis Cartilage 2010, 18:150-159.
137. Karsdal M.A., Byrjalsen I., Bay-Jensen A.C., Henriksen K., Riis B.J., Christiansen C. Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis-the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation. BMC Musculoskelet Disord 2010, 11:125.
138. Manicourt D.H., Azria M., Mindeholm L., Thonar E.J., Devogelaer J.P. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 2006, 54:3205-3211.
139. Sniekers Y.H., Weinans H., Bierma-Zeinstra S.M., van Leeuwen J.P., van Osch G.J. Animal models for osteoarthritis: the effect of ovariectomy and estrogen treatment - a systematic approach. Osteoarthritis Cartilage 2008, 16:533-541.
140. Christgau S., Tanko L.B., Cloos P.A., Mouritzen U., Christiansen C., Delaisse J.M., et al. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause 2004, 11:508-518.
141. Gineyts E., Mo J.A., Ko A., Henriksen D.B., Curtis S.P., Gertz B.J., et al. Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Ann Rheum Dis 2004, 63:857-861.
142. Pelletier J.P., Raynauld J.P., Caron J., Mineau F., Abram F., Dorais M., et al. Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis. Ann Rheum Dis 2010, 69:2095-2101.
143. Shimizu M., Higuchi H., Takagishi K., Shinozaki T., Kobayashi T. Clinical and biochemical characteristics after intra-articular injection for the treatment of osteoarthritis of the knee: prospective randomized study of sodium hyaluronate and corticosteroid. J Orthop Sci 2010, 15:51-56.
144. Olsen A.K., Sondergaard B.C., Byrjalsen I., Tanko L.B., Christiansen C., Muller A., et al. Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen. Osteoarthritis Cartilage 2007, 15:335-342.
145. Nemirovskiy O.V., Sunyer T., Aggarwal P., Abrams M., Hellio Le Graverand M.P., Mathews W.R. Discovery and development of the N-terminal procollagen type II (NPII) biomarker: a tool for measuring collagen type II synthesis. Osteoarthritis Cartilage 2008, 16:1494-1500.
146. Nemirovskiy O.V., Dufield D.R., Sunyer T., Aggarwal P., Welsch D.J., Mathews W.R. Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo. Anal Biochem 2007, 361:93-101.
147. Bay-Jensen A.C., Liu Q., Byrjalsen I., Li Y., Wang J., Pedersen C., et al. Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM-increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin Biochem 2011, 44:423-429.
148. Charni-Ben Tabassi N., Richardot P., Toh L., Marotte H., Bay-Jensen A.C., Miossec P., et al. Circulating nitrated N-telopeptide of type III collagen (IIINys) as a biochemical marker of oxidative-related synovial tissue metabolism in rheumatoid arthritis. Ann Rheum Dis 2009, 68:451-452.
149. Richardot P., Charni-Ben Tabassi N., Toh L., Marotte H., Bay-Jensen A.C., Miossec P., et al. Nitrated type III collagen as a biological marker of nitric oxide-mediated synovial tissue metabolism in osteoarthritis. Osteoarthritis Cartilage 2009, 17:1362-1367.
150. Swearingen C.A., Carpenter J.W., Siegel R., Brittain I.J., Dotzlaf J., Durham T.B., et al. Development of a novel clinical biomarker assay to detect and quantify aggrecanase-generated aggrecan fragments in human synovial fluid, serum and urine. Osteoarthritis Cartilage 2010, 18:1150-1158.
151. Swearingen C.A., Chambers M.G., Lin C., Marimuthu J., Rito C.J., Carter Q.L., et al. A short-term pharmacodynamic model for monitoring aggrecanase activity: injection of monosodium iodoacetate (MIA) in rats and assessment of aggrecan neoepitope release in synovial fluid using novel ELISAs. Osteoarthritis Cartilage 2010, 18:1159-1166.
152. Carter Q.L., Dotzlaf J., Swearingen C., Brittain I., Chambers M., Duffin K., et al. Development and characterization of a novel ELISA based assay for the quantitation of sub-nanomolar levels of neoepitope exposed NITEGE-containing aggrecan fragments. J Immunol Methods 2007, 328:162-168.
153. Pratta M.A., Su J.L., Leesnitzer M.A., Struglics A., Larsson S., Lohmander L.S., et al. Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments. Osteoarthritis Cartilage 2006, 14:702-713.
154. Dufield D.R., Nemirovskiy O.V., Jennings M.G., Tortorella M.D., Malfait A.M., Mathews W.R. An immunoaffinity liquid chromatography-tandem mass spectrometry assay for detection of endogenous aggrecan fragments in biological fluids: use as a biomarker for aggrecanase activity and cartilage degradation. Anal Biochem 2011, 406:113-123.
155. Larsson S., Englund M., Struglics A., Lohmander L.S. Association between synovial fluid levels of aggrecan ARGS fragments and radiographic progression in knee osteoarthritis. Arthritis Res Ther 2012, 12:R230.
156. Wang B., Chen P., Jensen A.C., Karsdal M.A., Madsen S.H., Sondergaard B.C., et al. Suppression of MMP activity in bovine cartilage explants cultures has little if any effect on the release of aggrecanase-derived aggrecan fragments. BMC Res Notes 2009, 2:259.
157. Sumer E.U., Sondergaard B.C., Rousseau J.C., Delmas P.D., Fosang A.J., Karsdal M.A., et al. MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays. Osteoarthritis Cartilage 2007, 15:212-221.
158. Scuderi G.J., Golish S.R., Cook F.F., Cuellar J.M., Bowser R.P., Hanna L.S. Identification of a novel fibronectin-aggrecan complex in the synovial fluid of knees with painful meniscal injury. J Bone Joint Surg Am 2011, 93:336-340.
159. Lohmander L.S., Eyre D.R. Biochemical markers as surrogate end points of joint disease. Clinical trials in Rheumatoid Arthritis and Osteoarthritis 2007, 249-274.
160. Felson D.T., Lohmander L.S. Whither osteoarthritis biomarkers?. Osteoarthritis Cartilage 2009, 17:419-422.